Newsfeeds - Spark Newswire

1 minute read

Exelixis And Invenra Expand Collaboration To Discover And Develop Novel Biologics In Oncology

Today, 10:58 AM

Exelixis, Inc. (NASDAQ:EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. The augmented partnership builds on the two

EXEL

1 minute read

Earnings

Recap: Exelixis Q2 Earnings

By Benzinga Insights

Today, 10:58 AM

Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year to $0.37, which beat the estimate of $0.07.

EXEL

1 minute read

Exelixis Q2 Adj. EPS $0.37 Beats $0.07 Estimate, Sales $385.18M Beat $298.16M Estimate; Raises FY21 Sales Guidance To $1.3B-$1.4B vs $1.23B Est.

By Benzinga Newsdesk

Today, 10:58 AM

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.07 by 428.57 percent. This is a 48 percent increase over earnings of $0.25 per share from the same

EXEL

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 10:58 AM

Gainers

ENDP

1 minute read

Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer

By Vandana Singh

Today, 10:58 AM

The FDA has accepted Exelixis Inc’s (NASDAQ:EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC). The…

EXEL

2 minute read

FDA
News

Exelixis Announces U.S. FDA Accepts For Priority Review The Supplemental New Drug Application For CABOMETYX For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

By Benzinga Newsdesk

Today, 10:58 AM

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) as a treatment for

EXEL

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 10:58 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI